Actively Recruiting
Study of Pembrolizumab With or Without Chemotherapy and Investigational Agents in Treatment-Naive Adults With Stage IV Non-Small Cell Lung Cancer
Led by Merck Sharp & Dohme LLC · Updated on 2026-10-29
450
Participants Needed
47
Research Sites
34 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness and safety of pembrolizumab, with or without chemotherapy, combined with various investigational agents in treatment-naive participants diagnosed with advanced Stage IV squamous or non-squamous non-small cell lung cancer NSCLC. This trial is part of the larger pembrolizumab umbrella master protocol known as KEYMAKER-U01. Participants receive different combinations of pembrolizumab and investigational agents such as vibostolimab, boserolimab, MK-4830, MK-0482, Ifinatamab Deruxtecan I-DXd, and HER3-DXd. Treatments usually involve intravenous infusions every three weeks in cycles, with some agents given every six weeks during maintenance. The treatment duration can last up to approximately two years, including initial combination cycles followed by maintenance therapy. During the study, participants undergo regular assessments including tumor response evaluations, safety monitoring for adverse events and dose-limiting toxicities, as well as pharmacokinetic measurements of the study drugs. Screening procedures must be completed within specified windows before starting treatment. Researchers will follow participants for up to around two years to assess outcomes such as objective response rate, progression-free survival, and treatment tolerability.
CONDITIONS
Brief Title
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
Research Team
T
Toll Free Number
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here